Prosztatarák: vizsgálatok itt: Japán
43 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Bunkyo-ku, Fukuoka, Hidaka-shi, Kanazawa, Kita-gun, Kobe, Koshigaya-shi, Koto-ku, Matsuyama, Minato-ku, Nagoya, Osaka, Sagamihara-shi, Suita-shi, Toyama
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT07213674 - 3. fázisTaking peopleAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Chiba, Chūōku, Fukuoka, Hamamatsu, Kamakura-shi, Kanazawa, Kashiwa, Kobe, Kyoto, Sapporo, Suita-shi, Yokohama
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - 3. fázisTaking peopleStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Where
- Chiba, Chuo Ku, Fukuoka, Fukushima, Hiroshima, Kamakura, Kobe, Kumamoto, Kyoto, Nagoya, Sapporo, Yokohama
- Életkor
- 18 év to 100 év
- People
- 940 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06855277 - 1/2. fázisTaking peopleA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
- Where
- Fukuoka, Sapporo
- Életkor
- 18 év and over
- People
- 123 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07226986 · EU 2025-521859-23-00 - 3. fázisNot yet taking people in JapánSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Chiba, Fukuoka, Hiroshima, Kamakura-shi, Kawagoe-shi, Kisarazu-shi, Kita-gun, Kobe, Kumamoto, Maebashi, Nagano, Nagasaki, Nagoya, Osaka, Sakai, Sakura-shi, Sapporo, Suita-shi, Yokohama
- Életkor
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00 - 3. fázisTaking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Bunkyō City, Fukuoka, Kamakura-shi, Kawagoe-shi, Kawasaki-shi, Kisarazu-shi, Kumamoto, Kyoto, Maebashi, Miyazaki, Ōta-ku, Sagamihara-shi, Shimotsuke-shi, Yokohama
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - 3. fázisTaking peopleThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Chiba, Fukuoka, Kanazawa, Kobe, Kumamoto, Matsuyama, Osaka, Sapporo, Shinjuku-ku, Suita, Yamagata, Yokohama, Yokosuka
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - 1/2. fázisTaking peopleA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
- Where
- Kanagawa, Tokyo
- Életkor
- 18 év and over
- People
- 85 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06990880 · EU 2025-521581-10-00 - 3. fázisTaking peopleA Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
- Where
- Tokyo, Tottori
- Életkor
- 18 év and over
- People
- 684 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07802704 · EU 2026-525558-13-00 - 2. fázisTaking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Chūōku, Kashiwa, Kōtoku, Nagoya, Shinagawa-ku, Suita-shi
- Életkor
- 18 év to 130 év
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - 2/3. fázisTaking peopleOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Where
- Chiba, Fukuoka, Fukushima, Ishikawa, Kashiwa, Kobe, Kyoto, Sapporo, Yokohama
- Életkor
- 18 év to 100 év
- People
- 443 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06780670 · EU 2024-512342-42-00 - 1. fázisTaking peoplePhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Chuo Ku
- Életkor
- 18 év to 100 év
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - 1. fázisTaking peopleEvaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Where
- Chūōku
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT05983432 - 2. fázisTaking peopleA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Where
- Bunkyo-ku, Fukuoka, Kashiwa, Koto, Osaka, Sunto-gun
- Életkor
- 18 év and over
- People
- 218 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00 - 1/2. fázisTaking peopleA Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
- Where
- Chūōku, Hirakata-shi, Kashiwa
- Életkor
- 18 év and over
- People
- 52 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00 - 1. fázisNot yet taking people in JapánFirst-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Koto-ku, Yokohama
- Életkor
- 18 év and over
- People
- 198 worldwide
- Run by
- Bayer
See details and how to joinNCT06217822 · EU 2023-507486-26-00 - 1/2. fázisTaking peopleA Study of MT-4561 in Patients With Various Advanced Solid Tumors
- Where
- Chuo Ku, City
- Életkor
- 18 év and over
- People
- 27 worldwide
- Run by
- Tanabe Pharma America, Inc.
See details and how to joinNCT06943521 - No phaseNot yet taking people in JapánLTFU for All Cell and Gene Therapy Studies
- Where
- Kashiwa, Kyoto, Osakasayama-shi
- Életkor
- 18 év to 130 év
- People
- 64 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06194461